You’ve made injections work.
Now it’s technology’s turn.
Meet Hybrid Closed Loop: NHS-funded for eligible adults
Every meal, every walk, every 3 A.M. hypo: you work it out yourself. That's a lot of maths for one person.
Hybrid Closed Loop (or HCL) does a lot of that thinking for you. A sensor reads your glucose, a pump delivers your insulin, and an algorithm adjusts it every few minutes, day and night. You still tell it when you eat, it handles much of the rest.
Doing fine on injections? What if you could do better than fine?
Hybrid Closed Loop is designed to support you with some of the day-to-day insulin adjustments. Using a HCL system, like Omnipod® 5, you can see benefits like:
Less daily maths
Adjusts background insulin around the clock, so you're not crunching numbers all day.
Better nights
Keeps working—even while you sleep— easing off when your glucose drops and stepping up when it rises.
Proven HbA1c and TIR improvement
Proven to improve HbA1c and time in range compared with multiple daily injections with CGM, with no extra time spent low.1
A real-life perspective
See how Hybrid Closed Loop with Omnipod® 5 changed Richard's day-to-day.
“There’s no worrying about daily injections I used to take. It’s giving me more time to focus on my family… it’s made me happier and healthier”
Richard, Podder® since 2024
Can you get Hybrid Closed Loop on the NHS?
NICE recommends Hybrid Closed Loop for some adults with type 1, and NHS England is funding the rollout across England. You may be eligible if at least one of these applies to you:
- Your HbA1c is 58 mmol/mol (7.5%) or higher, even with a glucose sensor or pump
- You have hypos (lows) that disrupt your life, even with a glucose sensor or pump
- Children & young people with type 1 diabetes
- You're pregnant or planning a pregnancy*
This is the official NICE TA eligibility criteria. Your diabetes care team can explain the full criteria and what they mean for you.
You don’t have to work out the next step alone.
NHS England calls HCL “the next step in the evolution of diabetes technology”. Its five-year rollout is bringing HCL to eligible people across England. Access is being introduced step by step, so timing varies by area.
Ask your diabetes team. They can talk through whether HCL is suitable for you, explain local access and help you explore your options.
Omnipod® 5: The #1 pump chosen by pump users in Europe2
Going from injections to a pump can feel like a big leap. Omnipod 5 makes it a smaller one.
- No tubes. Nothing to tangle or catch. The Pod sticks to your skin, and you change it every 3 days (72 hours).
- Compatible with leading sensor brands*. Works with Dexcom G7 System, FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus sensors.
- Adjusts insulin delivery every 5 minutes. The Omnipod 5 algorithm does the fine-tuning.
Go into your next appointment ready to ask about Hybrid Closed Loop.
Download the guides for clear questions to ask your diabetes team, a simple checklist of information to have ready and NHS eligibility criteria in one place.
Frequently asked questions
About Hybrid Closed Loop
What is a Hybrid Closed Loop system and how does it work?
Can Hybrid Closed Loop prevent hypos (lows) and hypers (highs)?
What's the difference between Hybrid Closed Loop and closed loop?
Is Hybrid Closed Loop the same as an artificial pancreas?
About Access to Hybrid Closed Loop in the UK
Can I get a Hybrid Closed Loop system on the NHS?
What do NICE guidelines say about Hybrid Closed Loop systems?
My HbA1c is under 58 mmol/mol. Is it still worth asking?
Is Hybrid Closed Loop suitable if I already use a glucose sensor?
Do I have to choose Omnipod?
Will I be locked into one system for years?
I live in Scotland or Northern Ireland. Does this apply to me?
Want to learn more about HCL?
Explore practical information about HCL technology, sensors and insulin pumps in the Omnipod Learning Centre.
*A separate prescription is required for the sensor. The sensors are sold separately.
1. Wilmot E, et al. Lancet (2026); NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. HbA1c 13-weeks: control group 8% vs. Omnipod 5 group 7.2% (p<0.0001). TIR (70-180mg/dL or 3.9-10mmol/L) 13-weeks: control group 43% vs. Omnipod 5 group 65% (p<0.0001). TBR (<70 mg/dL or 3.9mmol/L) at 13-weeks: non-inferiority was met with 2.56% TBR with Omnipod 5.
2. Omnipod was the most frequently chosen pump by people with diabetes in a survey conducted by dQ&A with patients across Germany, Italy, France, United Kingdom, Netherlands, Sweden. n=101. H2 2025. P.48 (Dec 2025).
IMPORTANT SAFETY INFORMATION
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: The Omnipod 5 Algorithm should NOT be used by anyone under the age of 2 years old. The Omnipod 5 Algorithm should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycaemia or hyperglycaemia.